SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Fact Sheet WHO/204: hepatitis B. https://www.apps.who.int/inf-fs/en/fact204.html. Published October 2000. Accessed November 2010.
  • 2
    Chang T-T, Lai C-L, Chien R-N, Guan R, Lim S-G, Lee C-M, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-1282.
  • 3
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751.
  • 4
    Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
  • 5
    Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
  • 6
    Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
  • 7
    Curtis M, Hinkle J, Harris J, Borroto-Esoda K, Zhu Y. Tenofovir is equally active in vitro against wild-type HBV clinical isolates of genotypes A-H. Poster presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31-November 4, 2008; San Francisco, CA.
  • 8
    Heathcote EJ, Gane E, deMan R, Lee SS, Flisiak R, Manns M, et al. Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103). Poster presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30-November 3, 2009; Boston, MA.
  • 9
    Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-734.
  • 10
    Delaney WE IV, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 2471-2477.
  • 11
    Fung SK, Mazzulli T, Sherman M, Popovic V. Tenofovir (TDF) is effective in lamivudine (LAM)-resistant chronic hepatitis B patients who harbor rtA194T at baseline. Poster presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30-November 3, 2009; Boston, MA.
  • 12
    Qi X, Xiong S, Yang H, Miller M, Delaney WE IV. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-362.
  • 13
    van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
  • 14
    Berg T, Moller B, Trinh H, Chan S, Marcellin P, Suarez E, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV) [Abstract]. J Hepatol 2008; 48: S34.
  • 15
    Zhu Y, Curtis M, Harris J, Borroto-Esoda K. HBV DNA replication mediated by cloned patient RT gene and its use in virus phenotyping assay. Poster presented at: International Meeting of Molecular Biology of Hepatitis B Viruses; August 17-21, 2008; San Diego, CA.
  • 16
    Svarovskaia ES, Moser MJ, Bae AS, Prudent JR, Miller MD, Borroto-Esoda K. MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J Clin Microbiol 2006; 44: 4237-4241.
  • 17
    Moser MJ, Ruckstuhl M, Larsen CA, Swearingen AJ, Kozlowski M, Bassit L, et al. Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49: 3334-3340.
  • 18
    Snow-Lampart A, Sorbel J, Chappell BJ, Curtis M, Zhu Y, Borroto-Esoda K. Lack of tenofovir DF (TDF) resistance mutations in treatment-naive and treatment-experienced subjects with chronic HBV infection following 48 weeks of TDF mono therapy. Poster presented at: EASL Conference on Hepatitis B and C Virus Resistance to Antiviral Therapy; February 14-16, 2008; Paris, France.
  • 19
    Bartholomeusz A, Locarnini S. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int Antivir News 1997; 5: 123-124.
  • 20
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
  • 21
    Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25: 97-106.
  • 22
    van Bommel F, Trojan J, Wasmuth H, Huppe D, Moller B, Feucht HH, et al. Efficacy of tenofovir DF for the treatment of adefovir resistance. Poster presented at: 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2-6, 2007; Boston, MA.
  • 23
    Lada O, Gervais A, Branger M, Peytavin G, Colin G, Fraqueiro G, et al. Low rate of delayed response in lamivudine experienced HIV/HBV co-infected patients treated with tenofovir disoproxil fumarate (TDF) [Abstract]. J Hepatol 2008; 48: S230.
  • 24
    Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999; 29: 939-945.
  • 25
    Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, et al. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother 2007; 51: 2240-2243.
  • 26
    Berg T, Moller B, Trinh H, Chan S, Marcellin P, Suarez E, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF (FTC/TDF) for treatment of chronic hepatitis B (CHB) in patients with persistent viral replication receiving adefovir dipivoxil. Poster presented at: 44th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2009; Copenhagen, Denmark.
  • 27
    Lavocat F, Pichoud C, Deny P, Borroto-Esoda K, Sorbel J, Rousseau F, et al. Evolution of viral load and genome sequence in a clinical trial of tenofovir/emtricitabine combination versus tenofovir monotherapy for patients with previous adefovir dipivoxil failure. Poster presented at: 44th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2009; Copenhagen, Denmark.